A 62-Year-Old With Type 2 Diabetes, CKD, and a Mismatched Glucose Pattern
A 62-year-old woman with type 2 diabetes of 14 years, hypertension, and stage 3b chronic kidney disease (eGFR 36 mL/min/1.73 m², urine albumin-to-creatinine ratio 480 mg/g) comes for follow-up. Her medications are metformin 1000 mg twice daily, glipizide 10 mg daily, lisinopril 40 mg daily, and atorvastatin 40 mg daily. A1c is 9.4%. She describes two episodes in the past month of shakiness and sweating relieved by juice. Home fasting glucose values run 90–110 mg/dL, but post-meal readings are 220–280 mg/dL. She has gained 4 kg since her last visit and reports mild bilateral foot numbness. Blood pressure is 148/86, pulse 76. She takes ibuprofen 400 mg most evenings for knee pain.
1. Which medication changes would you make today, and which would you defer? Justify each.
Read the worked answer
Change now
- Stop glipizide. She has symptomatic hypoglycemia with fasting glucose of 90–110. Sulfonylureas cause glucose-independent insulin release and accumulate in CKD, so the drug is producing lows while doing nothing for her post-meal excursions. Tapering is reasonable; hypoglycemia risk falls quickly.
- Reduce metformin to 500 mg twice daily. At eGFR 30–45 the labeled maximum is 1000 mg/day, and the drug should not be newly started below 45. Stop entirely if eGFR falls under 30. Also check B12 - long-term metformin plus her foot numbness makes deficiency a real possibility.
- Add an SGLT2 inhibitor (e.g., dapagliflozin 10 mg). eGFR 36 is above the threshold for initiation, and with albuminuria of 480 mg/g she gets kidney and heart protection plus modest A1c and weight benefit without hypoglycemia. Expect a small reversible eGFR dip; counsel on genital infections, sick-day holding, and euglycemic DKA.
- Stop the ibuprofen. NSAID plus ACE inhibitor plus CKD is a classic triple-hit for AKI and blunts her blood pressure control. Substitute topical diclofenac, acetaminophen, and physical therapy.
Defer or sequence
- Blood pressure 148/86 with albuminuria on maximal ACE inhibitor: add a thiazide-like diuretic or dihydropyridine calcium channel blocker, or consider finerenone given the albuminuria, but check potassium and creatinine 1–2 weeks after each change rather than stacking adjustments.
- GLP-1 receptor agonist if A1c remains above goal after these changes - good efficacy and kidney outcome data, but cost and access need discussion.
- Keep atorvastatin 40 mg; target an individualized A1c around 7.5–8% given CKD and hypoglycemia history.
2. Her A1c is 9.4% but her fasting glucose is normal. Explain the physiology and how you would monitor going forward.
Read the worked answer
Why the numbers diverge
- A1c is a weighted average of glucose over roughly 12 weeks; her average is high because of daytime excursion, not because of fasting hyperglycemia.
- The pattern - flat fasting, steep post-meal rise - reflects loss of first-phase insulin secretion, impaired incretin effect, and accelerated early gastric emptying, all typical of long-standing type 2 diabetes. Her sulfonylurea keeps the fasting number artificially low while leaving mealtime hyperglycemia unopposed.
- Before accepting the A1c at face value, confirm it is valid: CKD with anemia, iron deficiency, or recent transfusion can shift A1c in either direction. Send a CBC and ferritin.
Monitoring plan
- Ask her to pair readings before and 2 hours after a meal rather than checking only fasting, so the post-meal burden becomes visible to her and to you.
- A 10–14 day continuous glucose monitor is very reasonable here - she has documented hypoglycemia on a sulfonylurea, and time-in-range data will tell you whether the lows disappear once glipizide is stopped.
- Recheck A1c and eGFR in 3 months, potassium and creatinine in 1–2 weeks after the medication changes. If the A1c does not fall once adherence and the post-meal pattern are addressed, escalate rather than re-adding a secretagogue.
3. What else must be addressed at this visit, and when will you see her again?
Read the worked answer
Same visit
- Feet: monofilament and vibration testing, skin and nail inspection; her numbness needs to be documented and staged, not just noted.
- Kidney safety: reinforce sick-day rules (hold metformin, SGLT2 inhibitor, ACE inhibitor, and diuretic during vomiting or dehydration) and caution against NSAIDs and iodinated contrast without preparation.
- Vaccines and screening: hepatitis B, pneumococcal, influenza, and zoster vaccination; retinal exam; dental care; depression and sleep apnea screening (obesity, hypertension, nocturia).
- Knee pain: she is using an NSAID nightly because nothing else has been offered - this is a treatment gap, not just a medication to remove.
Follow-up timing
- 2 weeks by phone or visit: hypoglycemia resolved? Home blood pressures? Potassium and creatinine after the diuretic or finerenone decision.
- 4 weeks: knee pain and function, B12 result, tolerance of the SGLT2 inhibitor.
- 3 months: A1c, eGFR, urine albumin-to-creatinine ratio, blood pressure, weight.
The organizing idea is that her A1c is not the only problem on the page - the hypoglycemia, the albuminuria, the NSAID, and the untreated knee are all active issues with different clocks.